Where is dihydroergotamine mesylate in the changing landscape of migraine therapy?
Authors:
- John A MorrenJMJohn A Morren
- Nestor Galvez-JimenezNGNestor Galvez-Jimenez
- 19 October 2010
- journal article
- review article
- Published by Informa Healthcare in Expert Opinion on Pharmacotherapy
- Vol. 11 (18) , 3085-3093
Abstract
Importance of the field: Migraine affects approximately 18% of women and 6% of men, and has an immense impact on quality of life and productivity. Advancement in therapeutic options has been slow. For many patients with difficult-to-treat migraine, the appropriate use of dihydroergotamine mesylate (DHE) can result in treatment success and unprecedented patient satisfaction. Areas covered in this review: Migraine treatment guidelines regarding the role of DHE are highlighted. An overview of the market for antimigraine drugs is provided in the context of DHE, since its introduction in 1943, and the novel agents that are likely to be available in the near future. An extensive literature search was undertaken using Medline and the Cochrane Systematic Review and Clinical Trial databases. What the reader will gain: An understanding of which migraine patients are likely to benefit maximally from treatment with DHE in its various forms. Take home message: In the most difficult patient groups – including those wit...Keywords
This publication has 32 references indexed in Scilit:
- Reduced Adverse Event Profile of Orally Inhaled DHE (MAP0004) vs IV DHE: Potential MechanismHeadache: The Journal of Head and Face Pain, 2009
- Migraine and cardiovascular disease: systematic review and meta-analysisBMJ, 2009
- Inpatient Treatment of Status Migraine With Dihydroergotamine in Children and AdolescentsHeadache: The Journal of Head and Face Pain, 2009
- Randomized, double-blind, placebo-controlled study of the safety, tolerability and pharmacokinetics of MAP0004 (orally-inhaled DHE) in adult asthmaticsCurrent Medical Research and Opinion, 2008
- Pharmacology of Dihydroergotamine and Evidence for Efficacy and Safety in MigraineHeadache: The Journal of Head and Face Pain, 2006
- Effectiveness of Subcutaneous Dihydroergotamine by Home Injection for MigraineHeadache: The Journal of Head and Face Pain, 1996
- fficacy, Safety, and Tolerability of Dihydroergotamine Nasal Spray as Monotherapy in the Treatment of Acute MigraineHeadache: The Journal of Head and Face Pain, 1995
- Office‐Based Treatment of Acute Migraine With Dihydroergotamine MesylateHeadache: The Journal of Head and Face Pain, 1993
- Thirty-Fourth Annual Scientific Meeting The American Association for the Study of Headache June 26-28, 1992,Toronto, CanadaHeadache: The Journal of Head and Face Pain, 1992
- Repetitive Intravenous DHE in the Treatment of Refractory HeadacheHeadache: The Journal of Head and Face Pain, 1990